[144] PTC Therapeutics, Inc. SEC Filing
PTC Therapeutics (PTCT) filed a Form 144 notifying the proposed sale of 2,813 common shares held at Fidelity Brokerage Services, with an aggregate market value of $136,646.45, and an approximate sale date of 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 via an option granted 02/15/2024 and payment will be in cash. The filing also lists two prior sales by the same person in May 2025 totaling 2,812 shares for gross proceeds of $129,715.92. The filer affirms no undisclosed material adverse information.
PTC Therapeutics (PTCT) ha depositato un Form 144 notificando la proposta vendita di 2.813 azioni ordinarie detenute presso Fidelity Brokerage Services, con un valore di mercato complessivo di $136.646,45 e una data di vendita approssimativa del 08/15/2025 su NASDAQ. Le azioni sono state acquisite il 08/15/2025 tramite un'opzione concessa il 02/15/2024 e il pagamento sar脿 effettuato in contanti. Il documento segnala inoltre due vendite precedenti dalla stessa persona, avvenute a maggio 2025, per un totale di 2.812 azioni e proventi lordi pari a $129.715,92. Il dichiarante afferma l'assenza di informazioni negative rilevanti non divulgate.
PTC Therapeutics (PTCT) present贸 un Form 144 notificando la propuesta de venta de 2.813 acciones ordinarias que mantiene en Fidelity Brokerage Services, por un valor de mercado agregado de $136,646.45 y con una fecha estimada de venta el 08/15/2025 en NASDAQ. Las acciones fueron adquiridas el 08/15/2025 mediante una opci贸n otorgada el 02/15/2024 y el pago se realizar谩 en efectivo. La presentaci贸n tambi茅n enumera dos ventas previas de la misma persona en mayo de 2025 por un total de 2.812 acciones y unos ingresos brutos de $129,715.92. El declarante afirma que no existe informaci贸n negativa material no divulgada.
PTC Therapeutics (PTCT)電� Fidelity Brokerage Services鞐� 氤挫湢 欷戩澑 2,813 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 鞎岆Μ電� Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 齑� 鞁滉皜齑濎暋鞚� $136,646.45鞚措┌, NASDAQ鞐愳劀鞚� 雽�霝奠爜鞚� 毵る弰鞚检潃 08/15/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞚� 欤检嫕霌れ潃 02/15/2024鞐� 攵�鞐悳 鞓奠厴鞚� 韱淀暣 08/15/2025鞐� 旆摑霅橃棃瓿�, 瓴办牅電� 顺勱笀鞙茧 鞚措（鞏挫 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊鞐愲姅 霃欖澕鞚胳澊 2025雲� 5鞗旍棎 鞚挫爠鞐� 毵る弰頃� 2,812欤�(齑� 毵れ稖鞎� $129,715.92)霃� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頄堨姷雼堧嫟.
PTC Therapeutics (PTCT) a d茅pos茅 un formulaire 144 notifiant la vente propos茅e de 2 813 actions ordinaires d茅tenues chez Fidelity Brokerage Services, pour une valeur de march茅 totale de $136,646.45, avec une date approximative de vente le 08/15/2025 sur le NASDAQ. Les actions ont 茅t茅 acquises le 08/15/2025 via une option accord茅e le 02/15/2024 et le paiement se fera en 别蝉辫猫肠别蝉. Le d茅p么t mentionne 茅galement deux ventes ant茅rieures par la m锚me personne en mai 2025 totalisant 2 812 actions pour des produits bruts de $129,715.92. Le d茅clarant affirme qu'il n'existe pas d'informations d茅favorables importantes non divulgu茅es.
PTC Therapeutics (PTCT) hat ein Form 144 eingereicht, in dem der geplante Verkauf von 2.813 Stammaktien, gehalten bei Fidelity Brokerage Services, mit einem Gesamtmarktwert von $136.646,45 und einem voraussichtlichen Verkaufstermin am 08/15/2025 an der NASDAQ gemeldet wird. Die Aktien wurden am 08/15/2025 眉ber eine am 02/15/2024 gew盲hrte Option erworben, die Zahlung erfolgt in Bargeld. Die Einreichung nennt au脽erdem zwei fr眉here Verk盲ufe derselben Person im Mai 2025 眉ber insgesamt 2.812 Aktien mit Bruttoerl枚sen von $129.715,92. Der Melder best盲tigt, dass keine nicht offengelegten, wesentlichen nachteiligen Informationen vorliegen.
- Disclosure compliance: The filer submitted a Form 144 detailing the proposed sale, acquisition source, broker, and approximate sale date.
- Transaction transparency: Includes prior sales in May 2025, showing recent disposition history rather than a single undisclosed event.
- Insider sale: The person intends to sell 2,813 shares, which may be viewed negatively by some investors despite small size.
- Concentration of holdings: All reported shares are held at a single broker (Fidelity Brokerage Services LLC), which could concentrate execution risk.
Insights
TL;DR: Insider plans a modest sale of 2,813 shares, previously sold ~2,812 shares in May; likely limited market impact.
The filing documents a planned sale tied to an option exercise and subsequent cash sale of 2,813 common shares valued at $136,646.45. Recent sales in May of similar aggregate size suggest this is personal liquidity rather than a signal of company-wide issues. The quantity represents a very small portion of the outstanding share count (2,813 of 79,438,094), so market and valuation impact should be minimal. Compliance with Rule 144 is properly documented.
TL;DR: Documentation appears complete and includes the required insider representation; no governance red flags disclosed.
The Form 144 includes acquisition details, broker information, and recent disposition history, and the signer affirms absence of undisclosed material information. The sale stems from stock options granted in 2024 and is scheduled for August 15, 2025. From a governance perspective, the filing is routine and transparent; it does not disclose any departures, related-party transactions, or compliance exceptions.
PTC Therapeutics (PTCT) ha depositato un Form 144 notificando la proposta vendita di 2.813 azioni ordinarie detenute presso Fidelity Brokerage Services, con un valore di mercato complessivo di $136.646,45 e una data di vendita approssimativa del 08/15/2025 su NASDAQ. Le azioni sono state acquisite il 08/15/2025 tramite un'opzione concessa il 02/15/2024 e il pagamento sar脿 effettuato in contanti. Il documento segnala inoltre due vendite precedenti dalla stessa persona, avvenute a maggio 2025, per un totale di 2.812 azioni e proventi lordi pari a $129.715,92. Il dichiarante afferma l'assenza di informazioni negative rilevanti non divulgate.
PTC Therapeutics (PTCT) present贸 un Form 144 notificando la propuesta de venta de 2.813 acciones ordinarias que mantiene en Fidelity Brokerage Services, por un valor de mercado agregado de $136,646.45 y con una fecha estimada de venta el 08/15/2025 en NASDAQ. Las acciones fueron adquiridas el 08/15/2025 mediante una opci贸n otorgada el 02/15/2024 y el pago se realizar谩 en efectivo. La presentaci贸n tambi茅n enumera dos ventas previas de la misma persona en mayo de 2025 por un total de 2.812 acciones y unos ingresos brutos de $129,715.92. El declarante afirma que no existe informaci贸n negativa material no divulgada.
PTC Therapeutics (PTCT)電� Fidelity Brokerage Services鞐� 氤挫湢 欷戩澑 2,813 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 鞎岆Μ電� Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 齑� 鞁滉皜齑濎暋鞚� $136,646.45鞚措┌, NASDAQ鞐愳劀鞚� 雽�霝奠爜鞚� 毵る弰鞚检潃 08/15/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞚� 欤检嫕霌れ潃 02/15/2024鞐� 攵�鞐悳 鞓奠厴鞚� 韱淀暣 08/15/2025鞐� 旆摑霅橃棃瓿�, 瓴办牅電� 顺勱笀鞙茧 鞚措（鞏挫 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊鞐愲姅 霃欖澕鞚胳澊 2025雲� 5鞗旍棎 鞚挫爠鞐� 毵る弰頃� 2,812欤�(齑� 毵れ稖鞎� $129,715.92)霃� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頄堨姷雼堧嫟.
PTC Therapeutics (PTCT) a d茅pos茅 un formulaire 144 notifiant la vente propos茅e de 2 813 actions ordinaires d茅tenues chez Fidelity Brokerage Services, pour une valeur de march茅 totale de $136,646.45, avec une date approximative de vente le 08/15/2025 sur le NASDAQ. Les actions ont 茅t茅 acquises le 08/15/2025 via une option accord茅e le 02/15/2024 et le paiement se fera en 别蝉辫猫肠别蝉. Le d茅p么t mentionne 茅galement deux ventes ant茅rieures par la m锚me personne en mai 2025 totalisant 2 812 actions pour des produits bruts de $129,715.92. Le d茅clarant affirme qu'il n'existe pas d'informations d茅favorables importantes non divulgu茅es.
PTC Therapeutics (PTCT) hat ein Form 144 eingereicht, in dem der geplante Verkauf von 2.813 Stammaktien, gehalten bei Fidelity Brokerage Services, mit einem Gesamtmarktwert von $136.646,45 und einem voraussichtlichen Verkaufstermin am 08/15/2025 an der NASDAQ gemeldet wird. Die Aktien wurden am 08/15/2025 眉ber eine am 02/15/2024 gew盲hrte Option erworben, die Zahlung erfolgt in Bargeld. Die Einreichung nennt au脽erdem zwei fr眉here Verk盲ufe derselben Person im Mai 2025 眉ber insgesamt 2.812 Aktien mit Bruttoerl枚sen von $129.715,92. Der Melder best盲tigt, dass keine nicht offengelegten, wesentlichen nachteiligen Informationen vorliegen.
FAQ
What does the PTCT Form 144 report?
Who is the broker handling the sale in the PTCT filing?
How and when were the shares being sold acquired?
Has the filer sold PTCT shares recently?
How large is the proposed sale relative to outstanding shares?
